ANI Pharma (ANIP) Misses Q2 EPS by 21c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ANIP Hot Sheet
Join SI Premium – FREE
ANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $1.13, $0.21 worse than the analyst estimate of $1.34. Revenue for the quarter came in at $47.3 million versus the consensus estimate of $51.42 million.
GUIDANCE:
ANI Pharma sees FY2018 EPS of $4.80-$5.27, versus the consensus of $5.74. ANI Pharma sees FY2018 revenue of $195-205 million.
For earnings history and earnings-related data on ANI Pharma (ANIP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
- Kotak Upgrades Shriram Finance Ltd (SHFL:IN) to Buy (1)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
